Elevated pulse pressure and risk of chronic kidney disease by hypertension status: A longitudinal study in Japanese adults

Author's affiliation

Yukari Okawa[1,2] and Toshiharu Mitsuhashi[3]

[1]Department of Public Health and Welfare, Zentsuji City Hall, 2-1-1 Bunkyo-cho, Zentsuji, Kagawa 765-8503, Japan
[2]Clinical Research Institute, Ohara HealthCare Foundation, 1-1-1 Miwa, Kurashiki, Okayama 710-8602, Japan
[3]Center for Innovative Clinical Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, Okayama 700-8558, Japan

ORCiD

Yukari Okawa: https://orcid.org/0000-0002-1704-6609
Toshiharu Mitsuhashi: https://orcid.org/0000-0001-9940-0570

Corresponding author

Yukari Okawa
Department of Public Health and Welfare, Zentsuji City Hall, 2-1-1 Bunkyo-cho, Zentsuji, Kagawa 765-8503, Japan
Tel.   +81 877 63 6308
Fax.   +81 877 63 6368
E-mail   okw3923@gmail.com

Abstract

Background and Aims

Little is known about the relationship between pulse pressure (PP) and incident chronic kidney disease (CKD) in Asian populations, particularly when analyzed separately by hypertension status. This study aims to assess the association between PP and the subsequent incidence of CKD in Japanese adults.

Methods

This longitudinal study included middle-aged and older Japanese citizens screened by the administrative checkup (1998–2024) conducted by Zentsuji City. The relationship between PP (subtracting diastolic blood pressure [BP] from systolic BP) and incident CKD (estimated filtration rate of <60 mL/min/1.73m^2) was evaluated by hypertension status, using the Weibull accelerated failure time model. PP was treated as time-varying, and categorized into <40 (reference), 40–<60, and ≥60 mmHg. In addition to the crude model, two adjusted models were performed, controlling for potential confounders.

Results

Of 15788 participants, 8881 (men: 42.7%) remained in this study. The mean follow-up time was 6.21 years for non-hypertension and 6.27 years for hypertension. The higher the PP, the higher the incidence rate regardless of prevalent hypertension. In non-hypertensive participants with PP ≥60 mmHg, a 10% shorter survival to CKD (95% confidence interval: 3%–16%) was observed, compared to PP <40 mmHg. In hypertensive participants, attenuated results were observed, with all 95% confidence intervals crossing the null value.

Conclusions

Higher PP may serve as a handy indicator for the development of CKD in non-hypertensive Japanese populations. Regular BP monitoring may assist in considering strategies for the public health prevention of CKD, especially for non-hypertensive Asian populations.

Keywords

Atherosclerosis; Blood pressure, Hypertension; Kidney diseases; Longitudinal studies; Risk factors

Introduction

Pulse pressure (PP) is one of the indicators representing arterial stiffness[1]. PP can be calculated simply by subtracting diastolic blood pressure (DBP) from systolic blood pressure (SBP). Since blood pressure (BP) is a routinely measured non-invasive test in clinical practice, PP is a useful index for assessing disease risk and prevention. To date, elevated PP has been reported to be associated with an increased risk of cardiovascular disease (CVD) events, stroke, and mortality[1–4].

PP plays an important role in the new-onset chronic kidney disease (CKD). To date, various follow-up studies of adult participants across multiple ethnic groups have assessed the relationship between PP and incident CKD under different conditions. For example, Sweden, Japan, and China conducted cohort studies from different perspectives[2,5,6]. In summary, all three studies agreed that higher baseline PP is associated with incident CKD. However, they included different racial populations and used different analytical conditions in middle-aged and older adults: the Swedish study from the Good Aging in Skåte (GÅS) included Swedish and compared PP 60–<70, 70–<80, ≥80 mmHg versus PP <60 mmHg; the Japanese study from the Kansai Healthcare Study (KHS) included only male Japanese and compared the 4th quartile (PP ≥56 mmHg) versus 1st quartile (PP ≤40 mmHg); and the Chinese study from the China Health and Retirement Longitudinal Study (CHARLS) included non-hypertensive Chinese and compared PP ≥60 mmHg versus PP <60 mmHg.

These three studies attempted to mitigate the influence of potential confounders such as age and body mass index (BMI). However, only one study from the CHARLS focused on the impact of hypertension status on the results, by including only non-hypertensive participants[7]. The relationship between PP and hypertension is bidirectional, and hypertension impairs renal function[8,9]. Additionally, according to the National Health and Nutrition Examination Survey (NHANES) in 2011–2014, non-Hispanic Asians tend to have a slightly lower prevalence of hypertension compared to non-Hispanic whites[10]. Thus, to more accurately assess the relationship between PP and CKD onset, it is important to stratify the results by hypertension status to evaluate its impact on PP, not only for both non-hypertensive and hypertensive participants but also within the same racial population to ensure the validity of the results.

Moreover, the effect of changes in PP over time is not negligible. A previous meta-analysis from seven cohort studies revealed that more visit-to-visit BP variability was associated with a higher risk of onset of CKD[11]. However, the previous studies have only investigated how baseline PP affects renal function, without considering the time-varying effect of PP throughout the entire follow-up period[5–7]. Accordingly, this longitudinal study aims to determine whether elevated time-varying PP shortens the time to onset of CKD in the middle-aged and older Japanese population with and without hypertension.

Materials and Methods

Data source and study participants

This secondary analysis study included all participants who underwent annual health checkups conducted by Zentsuji City, Kagawa Prefecture, Japan (participation ratio: 30%–40%)[12]. The target population for this checkup consists of citizens aged ≥40 years in the fiscal year (FY). In FY1998 and FY1999 only, citizens aged ≥35 years in FY were added to the target population under the city's health promotion initiatives targeting younger citizens. The same database as previous studies was used for data extraction on 1 July 2024[13–17].

In this study, participants were Japanese, had blood pressure and renal outcome observed, had no CKD at study entry, and had multiple observations. Missing observations of body mass index (BMI) and liver function tests were removed due to the small proportion of missingness of 0.01%.

Measurements

The annual health checkup includes measurements of height and weight, blood pressure, blood tests, urinalysis, and a self-reported questionnaire inquiring about medication use, medical history, and participants' lifestyle. All measurements were conducted in accordance with the protocol established by the Ministry of Health, Labour and Welfare (MHLW) of Japan[18]. No dietary restrictions were specified for checkups, and all measurements were conducted in both fasting and non-fasting states. Information on the time of the last meal was unavailable in this study. In this study, the data did not contain any medical history based on a physician's diagnosis.

Age in years and biological sex were verified by the city's database[12]. SBP and DBP were measured in mmHg. BMI was calculated by dividing participants' weight in kilograms by their height in meters squared. Blood tests include serum creatinine (SCr) test in mg/dL, cholesterol tests (the low-density lipoprotein cholesterol [LDL-C], the high-density lipoprotein cholesterol [HDL-C] in mg/dL, and triglycerides [TG] in mg/dL), hemoglobin A1c (HbA1c) test in %, and liver enzyme tests (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] in U/L). SCr was measured by the enzymatic method.

As of FY2013, Japan changed the default HbA1c reporting system to the National Glycohemoglobin Standardization Program (NGSP) from the Japan Diabetes Society (JDS) [19,20]. Therefore, $HbA1c_{JDS}$ was standardized to $HbA1c_{NGSP}$ using the officially certified conversion equation: $HbA1c_{NGSP} = 1.02 \times HbA1c_{JDS} + 0.25$[21].

In the questionnaire, smoking status was assessed by asking participants whether they habitually smoke, which was defined as smoking for at least 6 months or having smoked at least 100 cigarettes in total. Participants were asked about their frequency of alcohol intake (daily/sometimes/seldom or unable to drink). The use of antihypertensive agents, insulin or hypoglycemic agents, and antihyperlipidemic agents was asked with a "yes" or "no" response. The MHLW added questions regarding medication use in FY2012 and removed or modified the questions for individuals aged ≥75 in FY2020, which caused ≥50% of the total observations to be unmeasured[18].

Variables

Exposure variable: Pulse pressure

The exposure variable in this study was PP in mmHg, calculated by subtracting SBP minus DBP. There is no universally established cutoff value for elevated PP[22]. Empirically, PP was classified into three categories: <40 (reference), 40–<60, and ≥60 mmHg[7].

Outcome variable: Incident chronic kidney disease

The outcome variable was CKD incidence. Renal function was assessed based on the estimated glomerular filtration rate (eGFR), which was calculated using the three-variable equation for Japanese: eGFR in mL/min/1.73m^2 = $194 \times SCr^{-1.094} \times age^{-0.287}$ ($\times 0.739$ if female)[23,24]. CKD was defined as eGFR <60 mL/min/1.73m^2[24].

Other covariates

Age was treated as a continuous variable. Sex was categorized into male (reference) and female. Overweight or obese was defined as BMI ≥25.0 kg/m^2[25]. Hypertension was defined as SBP ≥130 mmHg or DBP ≥80 mmHg[10]. Dyslipidemia was defined as having LDL-C ≥140 mg/dL, HDL-C <40 mg/dL, or TG ≥150 mg/dL[26].

Self-reported smoking status was dichotomized into "non- or ex-smoker (reference)" or "smoker." Participants were regarded as having diabetes if their HbA1c was ≥6.5%[27]. Liver function was evaluated using the "De Ritis Ratio," calculated as AST level divided by ALT level[28,29].

Self-reported alcohol intake was categorized as "non- or seldom-drinker (reference)" for participants who answered "seldom or unable to drink" and as "drinker" for those who answered "daily" or "sometimes." Information on medication use was excluded from the analysis due to a large proportion of missing data among older participants aged ≥75 years, which may introduce age-related bias[18].

Statistical analysis

In this analysis, all analyses were conducted separately by hypertension status. The following binary variables were missing and were filled using a logistic regression imputation method with 40 imputations: self-reported alcohol intake (missing 31.2%), self-reported smoking status (missing 30.8%), dyslipidemia (missing 25.6%), and diabetes (missing 8.2%)[30]. Participants' characteristics throughout the follow-up period were summarized separately based on prevalent hypertension status, presenting the number of failures, person-years (PY), and incidence rate per 1000 PY (IR), averaged over 40 imputations if imputed[31]. Mean and standard deviations (SD) were shown for continuous variables.

Kaplan–Meier curves were created by the PP category, separated by hypertension status. The violation of the proportional hazards (PH) assumption was confirmed both statistically and graphically[32]. Therefore, the Weibull accelerated failure-time (AFT) model was selected based on the lower Akaike and Bayesian information criteria values[33,34]. The outcome measure was the time ratio (TR), where a TR less than one indicates a shorter time to CKD onset.

In addition to the crude model, Model 1 (adjusted for sex and age) and Model 2 (adjusted for sex, age, overweight or obesity, self-reported alcohol intake, self-reported smoking status, dyslipidemia, diabetes, and AST/ALT ratio) were presented, stratified by hypertension status. When interaction effects were observed between the PP category and the following variables, a multiplicative term was added to the model to improve model stability: age, overweight or obesity, self-reported alcohol intake, self-reported smoking status, dyslipidemia, diabetes, and AST/ALT ratio.

A two-tailed p-value of less than 0.05 was regarded as statistically significant. The flowchart was created using Python 3.11.7[35]. All other statistical analyses were conducted using Stata/MP 16.1 (StataCorp, College Station, TX, USA). This research followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline[36].

Sensitivity analyses

This study conducted two sensitivity analyses. First, to examine whether there were sex differences in the relationship between PP and incident CKD, all analyses were further stratified by sex. Second, to address the limitation of eGFR in underestimating CKD diagnosis, CKD was defined as eGFR <60 mL/min/1.73m^2 and/or dipstick proteinuria ≥1+[37].

Results

Initially, 15788 participants (men: 41.0%; mean age at study entry: 62.3) participated in this study. After exclusion (**Figure 1**), 8881 participants (men: 42.7%; mean age at study entry: 59.9; hypertensive at study entry: 54.2%) remained in the final cohort, with checkup dates ranging from 6 April 1998 to 10 June 2024. At study entry, the distributions of PP category of <40, 40–<60, and ≥60 mmHg, in order, were 16.5%, 55.3%,

and 28.2% for the total population, 27.9%, 68.1%, and 4.0% for non-hypertension, and 6.8%, 44.5%, and 48.7% for hypertension.

The total follow-up times were 37922.1 person-years for non-hypertensive participants and 41909.8 person-years for hypertensive participants (**Tables 1 and 2**). The distributions of time-varying PP categories of <40, 40–<60, and ≥60 mmHg were 25.2%, 69.1%, and 5.8% for non-hypertensive participants and 6.2%, 39.9%, and 53.9% for hypertensive participants. After the follow-up, 28.9% of 6682 hypertensive participants and 20.7% of 6106 non-hypertensive participants developed CKD. Regardless of hypertension status, a higher PP presented a higher incidence rate (IR) of CKD.

Figure 2 presents the Kaplan–Meier curves by the PP category stratified by hypertension status. Compared to the PP <40 mmHg, higher PP showed a shorter survival time to CKD onset in participants with and without hypertension (**Table 3**). A more distinct dose–response relationship was observed in non-hypertensive participants compared to hypertensive participants. In the highest category of PP ≥60 mmHg, the adjusted time ratios (aTR) were 0.90 (95% CI: 0.84–0.97) for non-hypertensive participants and 0.97 (95% CI: 0.93–1.01) for hypertensive participants, compared to the reference category of PP <40 mmHg. Hypertensive participants with higher PP categories had a 2%–3% shorter survival time to CKD by point estimate in the full model, with 95% CIs crossing one.

Sensitivity analyses

First sensitivity analysis: Sex stratification

In **Table S1**, the results were further stratified by sex. In men, the distribution of time-varying PP categories of <40, 40–60, and ≥60 mmHg was 24.3%, 69.9%, 5.9% for non-hypertension and 6.7%, 42.6%, and 50.7% for hypertension. Among women, the distribution was 25.8%, 68.5%, 5.7% for non-hypertension and 5.8%, 37.4%, and 56.8% for hypertension.

The results showed a somewhat similar trend in the main analysis; increased PP presented higher IRs of CKD, regardless of sex and hypertension status (**Table 2**). However, women exhibited a clearer dose–response relationship between PP and incident CKD compared to men. Specifically, in the non-hypertensive group, women with PP ≥60 mmHg had up to 32% shorter survival by point estimate, whereas men in the same category had a reduction of only 2%.

Second sensitivity analysis: CKD definition using eGFR and dipstick proteinuria

The results using the CKD regarded as eGFR <60 mL/min/1.73m^2 and/or proteinuria ≥1+ were shown in **Table S2**. With the CKD definition including eGFR and dipstick proteinuria, the total follow-up time was reduced by 7.7% for non-hypertensive participants and by 12.2% for hypertensive participants. At study entry, the distributions of PP categories of <40, 40–<60, and ≥60 mmHg were 16.6%, 55.7%, and 27.7% for the total population, 27.8%, 68.2%, and 4.0% for non-hypertension, and 6.8%, 44.9%, and 48.3% for hypertension. The distributions of time-varying PP categories were similar to the main analysis at 25.3%, 69.2%, and 5.5% for non-hypertension and 6.3%, 40.5%, and 53.2% for hypertension (**Tables 1 and 2**).

In all PP categories, the IRs of CKD were higher than those in the main analysis. The estimation results were consistent with those of the main analysis in participants with and without hypertension, with the shortest survival time to CKD at 13% (95% CI: 4%–21%) in non-hypertensive participants (**Table 3**).

Discussion

This longitudinal study confirmed that elevated PP shortens the time to incident CKD, particularly in non-hypertensive participants. A dose–response relationship was presented, with a 10% reduction (95% CI: 3%–16%) at maximum in non-hypertensive participants with PP ≥60 mmHg than those with PP <40 mmHg. The results of hypertensive participants showed only a 3% reduction with PP ≥60 mmHg, with the 95% CI crossing the null value. The results among non-hypertensive participants in this study were consistent with those of the Chinese non-hypertensive population from the CHARLS, with 1.34 times (95% CI: 1.02–1.75) higher risk of renal decline in those with PP ≥60 mmHg compared to those with PP <60 mmHg[7].

There are three potential reasons why the results were more clear in non-hypertensive participants. First, non-hypertensive participants with higher PP, a surrogate marker of arterial stiffness, may have been pre-hypertensive[1]. Healthy elastic arteries stretch during systole and recoil during diastole, ensuring efficient function, which results in increased diastolic flow and lower SBP and PP. Inversely, when the arterial rigidity is severe, the arteries do not stretch, causing the entire blood volume to flow directly through them, leading to elevated SBP and PP and reduced diastolic flow, causing higher BP and higher PP are strongly connected[38]. The trend of time-varying PP distribution was reversed depending on hypertension status in this study; the proportions of the follow-up time for time-varying PP ≥60 mmHg were 5.8% for non-hypertension and 53.9% for hypertension (**Tables 1 and 2**). Therefore, non-hypertensive participants with the highest PP category may have normal BP; however, they could be pre-hypertensive and have begun to lose arterial flexibility.

Second, hypertensive participants may have a detection problem. As described above, participants with higher BP tended to have higher PP. In hypertensive participants, only 6.2% of the entire follow-up time was in the reference category (<40 mmHg). This may cause the results to be more unstable, making it difficult to detect a relationship between elevated PP and the later onset of CKD. On the contrary, the reference PP category in non-hypertensive participants accounts for 25.2% of the total follow-up, suggesting the results can be more robust than that of hypertensive participants.

Third, the missing information on antihypertensive medication use may affect the results. As described in the Methods section, more than half of the self-reported medication data was missing due to a system-related issue, mainly among participants aged ≥75 years[18]. This missingness may lead to the misclassification of hypertensive participants on medication into non-hypertensive participants, which causes overestimation. However, according to the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), only 22.9% of all checkup participants aged 40 to 74 years in Kagawa Prefecture reported taking any antihypertensive medications in FY2022[39]. Moreover, when the first-line antihypertensive medications (e.g., calcium channel blockers) are taken, they widen the arteries, which lowers BP, reducing PP as well[40]. The proportion of hypertensive participants on antihypertensive medication may not be large, and "true" hypertensive participants with well-controlled BP by medication were more likely classified into the lower PP category, leading to underestimation. This suggests that the missingness of antihypertensive medication may not have a significant impact on the results.

We performed a stratification by sex (**Table S1**). The trends were generally similar to those in the main analysis (**Table 3**). Our study revealed that higher PP harms renal function faster in women than in men by point estimate, regardless of hypertension status. On the contrary, the association of PP and the development of CKD was nearly null in men. This is consistent with the previous study including male Japanese from the KHS, without adjustment for antihypertensive medication use, with aHRs (95% CIs) of 0.84(0.64–1.10) for the PP of 41–<48 mmHg, 0.93 (0.71–1.21) for the PP of 48–<56 mmHg, and 1.05 (0.81–1.35) for PP ≥56 mmHg, compared to the PP <40 mmHg[6].

The more noticeable results in women may stem from the vulnerability of increased PP due to a smaller aortic diameter, which leads to higher PP, and limited aortic remodeling after midlife, which causes arteriosclerosis[1]. This may explain why the impact of elevated PP on renal function is greater in women than in men, as observed in the present study.

Strengths and Limitations

The strengths of this research lie in the reliability of the data, which is derived from long-term longitudinal administrative checkup records (1998–2024) managed by the local government, which follows the protocol set by the MHLW[12,18]. Since checkups target relatively healthy residents living at home and capture people's conditions before severe disease progression, the findings of this study can be used in public health initiatives aimed at preventing the development of CKD through population-level interventions. Furthermore, this study treated the PP as a time-varying variable; therefore, this study more accurately reflects how long-term changes in PP impact the incidence of CKD.

However, several limitations of this study must be stated. First, owing to the nature of regular checkups implemented at a relatively low cost, the carotid-femoral pulse wave velocity (cf-PWV) data, which is a gold standard for aortic stiffness but a costly test in Japan, was unavailable in this study[41]. Second, the vulnerability of eGFR may influence the results. To understand this impact, in addition to the use of the estimation equation for the Japanese population for calculating eGFR, we defined CKD using eGFR plus dipstick proteinuria ≥1+, and confirmed the robustness of the results (**Table S2**)[23].

Third, this study is subject to influence from selection bias, as the participants tended to be healthier than the general population, which may make it difficult to generalize the results to other populations that include a higher proportion of unhealthy people[42]. Furthermore, the long follow-up period may lead to a built-in selection bias, as participants less likely to develop CKD remain in the study cohort, potentially underestimating the true association in this study[43]. Finally, the residual bias from unmeasured confounders remains in this study (e.g., physical activity, protein intake, uric acid, depression, socioeconomic status)[44–48]. However, the direction and magnitude of bias cannot be determined.

Conclusions

This longitudinal study among middle-aged and older Japanese found that elevated time-varying PP ≥60 mmHg was associated with a 10% shorter survival time to CKD in non-hypertensive participants, but attenuated results in hypertensive participants. This finding will be beneficial for the public health sectors in conducting a population-based health approach to prevent CKD in relatively healthy Asian adults without hypertension in the future.

Ethic

The data was anonymized before receipt. The Ethics Committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital approved this study (No. K1708-040). The Ethics committee waived the need for informed consent. This research followed the Declaration of Helsinki and Japanese Ethical Guidelines for Medical and Biological Research involving Human Subjects.

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest

Yukari Okawa is an employee of Zentsuji City.

Acknowledgments

We thank all participants in this study, Ayaka Nakatsu, Masako Matsumoto, Mayumi Kitadani, and the local government officers of Zentsuji City who kindly supported our research.

Author Contributions

Conceptualization, Y.O.; methodology, Y.O.; formal analysis, Y.O.; investigation, Y.O.; data curation, Y.O.; writing—original draft preparation, Y.O.; writing—review and editing, T.M., Y.O.; visualization, Y.O.; supervision, T.M.; project administration, Y.O.

References

[1] P. Boutouyrie, P. Chowienczyk, J.D. Humphrey, G.F. Mitchell, Arterial stiffness and cardiovascular risk in hypertension, Circulation Research 128 (2021) 864–886. https://doi.org/10.1161/CIRCRESAHA.121.318061.

[2] J.D. Melgarejo, L. Thijs, D.-M. Wei, M. Bursztyn, W.-Y. Yang, Y. Li, K. Asayama, T.W. Hansen, M. Kikuya, T. Ohkubo, E. Dolan, K. Stolarz-Skrzypek, Y.-B. Cheng, V. Tikhonoff, S. Malyutina, E. Casiglia, L. Lind, E. Sandoya, J. Filipovský, K. Narkiewicz, N. Gilis-Malinowska, K. Kawecka-Jaszcz, J. Boggia, J.-G. Wang, Y. Imai, P. Verhamme, S. Trenson, S. Janssens, E. O'Brien, G.E. Maestre, B. Gavish, J.A. Staessen, Z.-Y. Zhang, Relative and absolute risk to guide the management of pulse pressure, an age-related cardiovascular risk factor, American Journal of Hypertension 34 (2021) 929–938. https://doi.org/10.1093/ajh/hpab048.

[3] K. Miura, A.R. Dyer, P. Greenland, M.L. Daviglus, M. Hill, K. Liu, D.B. Garside, J. Stamler, Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovascular and all-cause mortality rates: The Chicago Heart Association Detection Project in Industry Study, Hypertension 38 (2001) 232–237. https://doi.org/10.1161/01.HYP.38.2.232.

[4] M.J. Domanski, B.R. Davis, M.A. Pfeffer, M. Kastantin, G.F. Mitchell, Isolated systolic hypertension: Prognostic information provided by pulse pressure, Hypertension 34 (1999) 375–380. https://doi.org/10.1161/01.HYP.34.3.375.

[5] T. Månsson, A. Rosso, K. Ellström, S. Elmståhl, Elevated pulse pressure preceded incident chronic kidney disease in the general older population in Sweden, Sci Rep 14 (2024) 15414. https://doi.org/10.1038/s41598-024-66458-3.

[6] H. Koh, T. Hayashi, K.K. Sato, N. Harita, I. Maeda, Y. Nakamura, G. Endo, H. Kambe, K. Fukuda, Blood pressure components and risk for chronic kidney disease in middle-aged Japanese men: The Kansai Healthcare Study, Hypertens Res 34 (2011) 536–541. https://doi.org/10.1038/hr.2011.2.

[7] H. Wang, Q. Meng, C. Yang, Y. Wang, G. Kong, Y. Zhao, F. Wang, L. Zhang, Association between pulse pressure, systolic blood pressure and the risk of rapid decline of kidney function among general population without hypertension: results from the China health and retirement longitudinal study (CHARLS), J Transl Med 19 (2021) 512. https://doi.org/10.1186/s12967-021-03176-8.

[8] H.D. Sesso, M.J. Stampfer, B. Rosner, C.H. Hennekens, J.M. Gaziano, J.E. Manson, R.J. Glynn, Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men, Hypertension 36 (2000) 801–807. https://doi.org/10.1161/01.HYP.36.5.801.

[9] M. Weldegiorgis, M. Woodward, The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis, BMC Nephrol 21 (2020) 506. https://doi.org/10.1186/s12882-020-02151-7.

[10] P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Casey, K.J. Collins, C. Dennison Himmelfarb, S.M. DePalma, S. Gidding, K.A. Jamerson, D.W. Jones, E.J. MacLaughlin, P. Muntner, B. Ovbiagele, S.C. Smith, C.C. Spencer, R.S. Stafford, S.J. Taler, R.J. Thomas, K.A. Williams, J.D. Williamson, J.T. Wright, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines, Hypertension 71 (2018) 1269–1324. https://doi.org/10.1161/HYP.0000000000000066.

[11] H. Li, J. Xue, W. Dai, Y. Chen, Q. Zhou, W. Chen, Visit-to-visit blood pressure variability and risk of chronic kidney disease: A systematic review and meta-analyses, PLoS ONE 15 (2020) e0233233. https://doi.org/10.1371/journal.pone.0233233.

[12] Zentsuji City, Zentsuji City official website, (n.d.). https://www.city.zentsuji.kagawa.jp (accessed March 26, 2025).

[13] Y. Okawa, E. Suzuki, T. Mitsuhashi, T. Tsuda, T. Yorifuji, A population-based longitudinal study on glycated hemoglobin levels and new-onset chronic kidney disease among non-diabetic Japanese adults, Sci Rep 13 (2023) 13770. https://doi.org/10.1038/s41598-023-40300-8.

[14] Y. Okawa, T. Mitsuhashi, Association between blood pressure and new onset of chronic kidney disease in non-diabetic Japanese adults: A population-based longitudinal study from 1998 to 2023, Nutrition, Metabolism and Cardiovascular Diseases 34 (2024) 2395–2404. https://doi.org/10.1016/j.numecd.2024.05.005.

[15] Y. Okawa, T. Mitsuhashi, E. Suzuki, Aspartate/alanine aminotransferase ratio and development of chronic kidney disease in non-diabetic men and women: a population-based longitudinal study in Kagawa, Japan, Clin Exp Nephrol (2024). https://doi.org/10.1007/s10157-024-02601-8.

[16] Y. Okawa, T. Mitsuhashi, Dyslipidemia and development of chronic kidney disease in non-diabetic Japanese adults: A 26-year, community-based, longitudinal study, Kidney and Dialysis 4 (2024) 246–256. https://doi.org/10.3390/kidneydial4040020.

[17] Y. Okawa, T. Mitsuhashi, T. Tsuda, The Asia-Pacific body mass index classification and new-onset chronic kidney disease in non-diabetic Japanese adults: A community-based longitudinal study from 1998 to 2023, Biomedicines 13 (2025) 373. https://doi.org/10.3390/biomedicines13020373.

[18] Ministry of Health, Labour and Welfare, Specific health examination and specific health guidance, (n.d.). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000161103.html (accessed March 26, 2025).

[19] NGSP, NGSP Home, (n.d.). https://ngsp.org (accessed March 26, 2025).

[20] The Japan Diabetes Society, The Japan Diabetes Society, (n.d.). http://www.jds.or.jp/modules/en (accessed March 26, 2025).

[21] A. Kashiwagi, M. Kasuga, E. Araki, Y. Oka, T. Hanafusa, H. Ito, M. Tominaga, S. Oikawa, M. Noda, T. Kawamura, T. Sanke, M. Namba, M. Hashiramoto, T. Sasahara, Y. Nishio, K. Kuwa, K. Ueki, I. Takei, M. Umemoto, M. Murakami, M. Yamakado, Y. Yatomi, H. Ohashi, Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society, International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values, Journal of Diabetes Investigation 3 (2012) 39–40. https://doi.org/10.1111/j.2040-1124.2012.00207.x.

[22] S.S. Martin, A.W. Aday, N.B. Allen, Z.I. Almarzooq, C.A.M. Anderson, P. Arora, C.L. Avery, C.M. Baker-Smith, N. Bansal, A.Z. Beaton, Y. Commodore-Mensah, M.E. Currie, M.S.V. Elkind, W. Fan, G. Generoso, B.B. Gibbs, D.G. Heard, S. Hiremath, M.C. Johansen, D.S. Kazi, D. Ko, M.H. Leppert, J.W. Magnani, E.D. Michos, M.E. Mussolino, N.I. Parikh, S.M. Perman, M. Rezk-Hanna, G.A. Roth, N.S. Shah, M.V. Springer, M.-P. St-Onge, E.L. Thacker, S.M. Urbut, H.G.C. Van Spall, J.H. Voeks, S.P. Whelton, N.D. Wong, S.S. Wong, K. Yaffe, L.P. Palaniappan, on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee, 2025 Heart disease and stroke

statistics: A report of US and global data from the American Heart Association, Circulation (2025) CIR.0000000000001303. https://doi.org/10.1161/CIR.0000000000001303.

[23] S. Matsuo, Y. Yasuda, E. Imai, M. Horio, Current status of estimated glomerular filtration rate (eGFR) equations for Asians and an approach to create a common eGFR equation: approach to eGFR equation for Asians, Nephrology 15 (2010) 45–48. https://doi.org/10.1111/j.1440-1797.2010.01313.x.

[24] P.E. Stevens, S.B. Ahmed, J.J. Carrero, B. Foster, A. Francis, R.K. Hall, W.G. Herrington, G. Hill, L.A. Inker, R. Kazancıoğlu, E. Lamb, P. Lin, M. Madero, N. McIntyre, K. Morrow, G. Roberts, D. Sabanayagam, E. Schaeffner, M. Shlipak, R. Shroff, N. Tangri, T. Thanachayanont, I. Ulasi, G. Wong, C.-W. Yang, L. Zhang, A. Levin, KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease, Kidney International 105 (2024) S117–S314. https://doi.org/10.1016/j.kint.2023.10.018.

[25] World Health Organization, A healthy lifestyle - WHO recommendations, (n.d.). https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations (accessed March 26, 2025).

[26] T. Okamura, K. Tsukamoto, H. Arai, Y. Fujioka, Y. Ishigaki, S. Koba, H. Ohmura, T. Shoji, K. Yokote, H. Yoshida, M. Yoshida, J. Deguchi, K. Dobashi, A. Fujiyoshi, H. Hamaguchi, M. Hara, M. Harada-Shiba, T. Hirata, M. Iida, Y. Ikeda, S. Ishibashi, H. Kanda, S. Kihara, K. Kitagawa, S. Kodama, M. Koseki, Y. Maezawa, D. Masuda, T. Miida, Y. Miyamoto, R. Nishimura, K. Node, M. Noguchi, M. Ohishi, I. Saito, S. Sawada, H. Sone, M. Takemoto, A. Wakatsuki, H. Yanai, Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022, JAT 31 (2024) 641–853. https://doi.org/10.5551/jat.GL2022.

[27] American Diabetes Association Professional Practice Committee, N.A. ElSayed, G. Aleppo, R.R. Bannuru, D. Bruemmer, B.S. Collins, L. Ekhlaspour, J.L. Gaglia, M.E. Hilliard, E.L. Johnson, K. Khunti, I. Lingvay, G. Matfin, R.G. McCoy, M.L. Perry, S.J. Pilla, S. Polsky, P. Prahalad, R.E. Pratley, A.R. Segal, J.J. Seley, E. Selvin, R.C. Stanton, R.A. Gabbay, 2. Diagnosis and classification of diabetes: *Standards of care in diabetes—2024*, Diabetes Care 47 (2024) S20–S42. https://doi.org/10.2337/dc24-S002.

[28] M. Botros, K.A. Sikaris, The de ritis ratio: the test of time, Clin Biochem Rev 34 (2013) 117–130.

[29] H. Ochiai, T. Shirasawa, T. Yoshimoto, S. Nagahama, A. Watanabe, K. Sakamoto, A. Kokaze, Elevated alanine aminotransferase and low aspartate aminotransferase/alanine aminotransferase ratio are associated with chronic kidney disease among middle-aged women: a cross-sectional study, BMC Nephrol 21 (2020) 471. https://doi.org/10.1186/s12882-020-02144-6.

[30] R. Young, D.R. Johnson, Handling missing values in longitudinal panel data with multiple imputation, Fam Relat 77 (2015) 277–294. https://doi.org/10.1111/jomf.12144.

[31] P.T. von Hippel, How many imputations do you need? A two-stage calculation using a quadratic rule, Sociological Methods & Research 49 (2020) 699–718. https://doi.org/10.1177/0049124117747303.

[32] D. Schoenfeld, Partial residuals for the proportional hazards regression model, Biometrika 69 (1982) 239–241. https://doi.org/10.1093/biomet/69.1.239.

[33] H. Akaike, A new look at the statistical model identification, IEEE Trans. Automat. Contr. 19 (1974) 716–723. https://doi.org/10.1109/TAC.1974.1100705.

[34] G. Schwarz, Estimating the dimension of a model, Ann. Statist. 6 (1978). https://doi.org/10.1214/aos/1176344136.

[35] Python Software Foundation, Python, Python.Org (n.d.). https://www.python.org/ (accessed March 26, 2025).

[36] J.P. Vandenbroucke, E. von Elm, D.G. Altman, P.C. Gøtzsche, C.D. Mulrow, S.J. Pocock, C. Poole, J.J. Schlesselman, M. Egger, Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration, Epidemiology 18 (2007) 805–835. https://doi.org/10.1097/EDE.0b013e3181577511.

[37] T. Tanaka, S. Maruyama, N. Chishima, H. Akiyama, K. Shimamoto, S. Inokuchi, K. Yokota, A. Ozaki, Population characteristics and diagnosis rate of chronic kidney disease by eGFR and proteinuria in Japanese clinical practice: an observational database study, Sci Rep 14 (2024) 5172. https://doi.org/10.1038/s41598-024-55827-7.

[38] M. Briet, P. Boutouyrie, S. Laurent, G.M. London, Arterial stiffness and pulse pressure in CKD and ESRD, Kidney International 82 (2012) 388–400. https://doi.org/10.1038/ki.2012.131.

[39] Ministry of Health, Labour and Welfare, NDB Open Data, NDB Open Data (n.d.). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177182.html (accessed March 26, 2025).

[40] The Japanese Society of Hypertension, Japanese Society of Hypertension Guidelines for the Management of Hypertension 2019 (JSH2019), (2019). https://www.jpnsh.jp (accessed March 26, 2025).

[41] P. Salvi, F. Scalise, M. Rovina, F. Moretti, L. Salvi, A. Grillo, L. Gao, C. Baldi, A. Faini, G. Furlanis, A. Sorropago, S.C. Millasseau, G. Sorropago, R. Carretta, A.P. Avolio, G. Parati, Noninvasive estimation of aortic stiffness through different approaches: Comparison with intra-aortic recordings, Hypertension 74 (2019) 117–129. https://doi.org/10.1161/HYPERTENSIONAHA.119.12853.

[42] A.-L. Bjerregaard, H.T. Maindal, N.H. Bruun, A. Sandbæk, Patterns of attendance to health checks in a municipality setting: the Danish 'Check Your Health Preventive Program,' Preventive Medicine Reports 5 (2017) 175–182. https://doi.org/10.1016/j.pmedr.2016.12.011.

[43] M.A. Hernán, The hazards of hazard ratios, Epidemiology 21 (2010) 13–15. https://doi.org/10.1097/EDE.0b013e3181c1ea43.

[44] S. Seidu, M. Abdool, A. Almaqhawi, T.J. Wilkinson, S.K. Kunutsor, K. Khunti, T. Yates, Physical activity and risk of chronic kidney disease: systematic review and meta-analysis of 12 cohort studies involving 1,281,727 participants, Eur J Epidemiol 38 (2023) 267–280. https://doi.org/10.1007/s10654-022-00961-7.

[45] D.L.N. Gonçalves, T.R. Moreira, L.S. Da Silva, A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease, Sci Rep 12 (2022) 6251. https://doi.org/10.1038/s41598-022-10118-x.

[46] Y. Cheng, G. Zheng, Z. Song, G. Zhang, X. Rao, T. Zeng, Association between dietary protein intake and risk of chronic kidney disease: a systematic review and meta-analysis, Front. Nutr. 11 (2024) 1408424. https://doi.org/10.3389/fnut.2024.1408424.

[47] X. Zheng, W. Wu, S. Shen, Prospective bidirectional associations between depression and chronic kidney diseases, Sci Rep 12 (2022) 10903. https://doi.org/10.1038/s41598-022-15212-8.

[48] X. Zeng, J. Liu, S. Tao, H.G. Hong, Y. Li, P. Fu, Associations between socioeconomic status and chronic kidney disease: a meta-analysis, J Epidemiol Community Health 72 (2018) 270–279. https://doi.org/10.1136/jech-2017-209815.

Figures

Figure 1. Flow diagram of the study participants.

Figure 2. Kaplan–Meier curves stratified by hypertension status.

Tables

Table 1. Descriptive statistics of all observations stratified by the pulse pressure category among 6682 non-hypertensive Japanese citizens of Zentsuji City (27564 observations, 1998–2024).

| | Pulse pressure category | | | | | | | | | Total | | |
| | <40 mmHg | | | 40–<60 mmHg | | | ≥60 mmHg | | | | | |
	Failure	Person-years	IR*	Failure	Person-years	IR	Failure	Person-years	IR	Failure	Person-years	IR
Follow-up information												
Total		9555.4			26185.9			2180.9			37922.1	
Min/Max		0.48/25.3			0.40/25.8			0.42/16.5			0.40/25.8	
Mean/Median		3.79/2.09			4.85/3.11			1.98/1.11			6.21/4.04	
Failure/IR	234		24.5	905		34.6	124		56.9	1263		33.3
Variables												
Sex												
Male	81	3532.2	22.9	316	10169.7	31.1	39	851.7	45.8	436	14553.6	30.0
Female	153	6023.1	25.4	589	16016.2	36.8	85	1329.2	63.9	827	23368.5	35.4
Age in years, mean (SD)	61.5	(11.52)		66.6	(11.04)		72.9	(9.67)		66.1	(11.41)	
BMI category†												
Normal	196	8323.3	23.5	695	21116.5	32.9	94	1767.4	53.2	985	31207.1	31.6
Overweight or obese	38	1232.1	30.8	210	5069.4	41.4	30	413.5	72.5	278	6715.0	41.4
Self-reported drinking status												
Non- or seldom-drinker	137.1	5479.1	25.0	600.7	15558.1	38.6	90.9	1450.5	62.7	828.7	22487.7	36.9
Drinker	96.9	4076.2	23.8	304.3	10627.8	28.6	33.1	730.4	45.4	434.3	15434.4	28.1
Self-reported smoking status												
Non- or ex-smoker	208.8	7922.4	26.4	813.7	22179.6	36.7	111.8	1901.4	58.8	1134.2	32003.4	35.4
Smoker	25.2	1632.9	15.4	91.3	4006.3	22.8	12.3	279.5	43.8	128.8	5918.7	21.8
Dyslipidemia												
No	108.4	4651.2	23.3	398.4	12342.9	32.3	57.2	1083.9	52.8	564.0	18078.0	31.2
Yes	125.6	4904.1	25.6	506.6	13843.0	36.6	66.8	1097.0	60.9	699.0	19844.1	35.2
Diabetes												
No	218.6	9037.2	24.2	827.3	24079.7	34.4	109.8	1931.1	56.9	1155.7	35048.0	33.0
Yes	15.4	518.2	29.8	77.7	2106.2	36.9	14.2	249.8	56.9	107.3	2874.1	37.3
AST/ALT, mean (SD)	1.31	(0.45)		1.32	(0.44)		1.42	(0.47)		1.33	(0.44)	

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HbA1c, hemoglobin A1c; IR, incidence rate; Max, maximum; Min, minimum; PY, SD, standard deviation.

Results for multiple imputed variables (dyslipidemia, self-reported drinking status, self-reported smoking status, and diabetes) are averaged over 40 imputations.

Hypertension is defined as systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg.

* Incidence rate is reported per 1000 person-years.

† Overweight or obese is defined as a BMI ≥25 kg/m^2.

‡ Dyslipidemia is defined as serum low-density lipoprotein cholesterol ≥140 mg/dL, serum high-density lipoprotein cholesterol <40 mg/dL, and/or serum triglycerides ≥150 mg/dL.

¶ Diabetes is defined as HbA1c ≥6.5%.

Table 2. Descriptive statistics of all observations stratified by the pulse pressure category among 6682 hypertensive Japanese citizens of Zentsuji City (27564 observations, 1998–2024).

	Pulse pressure category									Total		
	<40 mmHg			40–<60 mmHg			≥60 mmHg					
	Failure	Person-years	IR*	Failure	Person-years	IR	Failure	Person-years	IR	Failure	Person-years	IR
Follow-up information												
Total		2608.3			16705.7			22595.9			41909.8	
Min/Max		0.46/23.0			0.37/25.2			0.19/25.5			0.19/25.9	
Mean/Median		2.45/1.18			3.84/2.28			4.78/3.03			6.27/4.23	
Failure/IR	77		29.5	661		39.6	1191		52.7	1929		46.0
Variables												
Sex												
Male	38	1308.2	29.0	259	8375.8	30.9	426	9958.4	42.8	723	19642.4	36.8
Female	39	1300.1	30.0	402	8329.8	48.3	765	12637.5	60.5	1206	22267.4	54.2
Age in years, mean (SD)	61.7	(10.61)		66.2	(10.07)		71.9	(8.82)		69.2	(9.96)	
BMI category†												
Normal	54	1897.5	28.5	428	10853.6	39.4	797	15527.2	51.3	1279	28278.3	45.2
Overweight or obese	23	710.8	32.4	233	5852.1	39.8	394	7068.6	55.7	650	13631.5	47.7
Self-reported drinking status												
Non- or seldom-drinker	37.2	1361.1	27.3	404.3	8781.6	46.0	779.4	13579.2	57.4	1220.9	23721.9	51.5
Drinker	39.8	1247.1	31.9	256.7	7924.1	32.4	411.6	9016.6	45.7	708.2	18187.9	38.9
Self-reported smoking status												
Non- or ex-smoker	65.6	2071.2	31.7	587.5	13827.2	42.5	1065.4	19525.1	54.6	1718.4	35423.6	48.5
Smoker	11.4	537.0	21.3	73.6	2878.5	25.6	125.7	3070.7	40.9	210.6	6486.2	32.5
Dyslipidemia												
No	21.4	927.7	23.0	243.9	6478.4	37.7	479.5	9017.3	53.2	744.8	16423.4	45.3
Yes	55.7	1680.5	33.1	417.1	10227.3	40.8	711.5	13578.5	52.4	1184.3	25486.4	46.5
Diabetes												
No	72.8	2419.4	30.1	603.0	15143.4	39.8	1056.1	19635.2	53.8	1731.9	37198.0	46.6
Yes	4.2	188.8	22.2	58.0	1562.3	37.1	134.9	2960.7	45.6	197.1	4711.8	41.8
AST/ALT, mean (SD)	1.21	(0.43)		1.25	(0.42)		1.35	(0.51)		1.30	(0.47)	

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HbA1c, hemoglobin A1c; IR, incidence rate; Max, maximum; Min, minimum; PY, SD, standard deviation.

Results for multiple imputed variables (dyslipidemia, self-reported drinking status, self-reported smoking status, and diabetes) are averaged over 40 imputations.

Hypertension is defined as systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg.

* Incidence rate is reported per 1000 person-years.

† Overweight or obese is defined as a BMI ≥25 kg/m^2.

‡ Dyslipidemia is defined as serum low-density lipoprotein cholesterol ≥140 mg/dL, serum high-density lipoprotein cholesterol <40 mg/dL, and/or serum triglycerides ≥150 mg/dL.

¶ Diabetes is defined as HbA1c ≥6.5%.

Table 3. New onset of chronic kidney disease according to the pulse pressure categories among 8881 non-hypertensive Japanese citizens of Zentsuji City (Total time at risk: 79831.9 PY, 1998–2024)

Pulse pressure classification	Non-hypertensive (n=6682; 37922.1 PY)						Hypertensive (n=6106; 41909.8 PY)					
	Follow-up information			Model			Follow-up information			Model		
				Crude	Model 1	Model 2				Crude	Model 1	Model 2
	Total PY	Failure	IR	TR (95% CI)	aTR (95% CI)	aTR (95% CI)	Total PY	Failure	IR	TR (95% CI)	aTR (95% CI)	aTR (95% CI)
<40 mmHg (reference)	9555.4	234	24.5	1.00	1.00	1.00	2608.3	77	29.5	1.00	1.00	1.00
40–<60 mmHg	26185.9	905	34.6	0.95 (0.91–0.99)	0.96 (0.92–1.00)	0.96 (0.92–1.00)	16705.7	661	39.6	0.97 (0.91–1.03)	0.98 (0.94–1.02)	0.98 (0.94–1.02)
≥60 mmHg	2180.9	124	56.9	0.88 (0.82–0.95)	0.90 (0.84–0.97)	0.90 (0.84–0.97)	22595.9	1191	52.7	0.95 (0.89–1.01)	0.97 (0.93–1.02)	0.97 (0.93–1.01)

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; aTR, adjusted time ratio; BMI, body mass index; BP, blood pressure; CI, confidence interval; HDL-C, HbA1c, hemoglobin A1c; high-density lipoprotein cholesterol; IR, incidence rate; LDL-C, low-density lipoprotein cholesterol; PY, person-years; TG, triglycerides; TR, time ratio.

Due to the change in hypertension status during follow-up, some participants were included in both hypertension categories.

Pulse pressure is calculated by subtracting DBP from SBP.

Hypertension is defined as SBP ≥130 mmHg and/or DBP ≥80 mmHg.

Overweight or obesity is defined as BMI ≥25 kg/m^2.

Dyslipidemia is defined as LDL-C ≥140 mg/dL, HDL-C <40 mg/dL, and/or TG ≥150 mg/dL.

Diabetes is defined as HbA1c ≥6.5%.

Model 1: Adjusted for sex (men [reference]/women) and age.

Model 2: Adjusted for both variables of Model 1, overweight or obesity (no [reference]/yes), self-reported alcohol intake (non- or seldom-drinker [reference]/drinker), self-reported smoking status (non- or ex-smoker [reference]/smoker), dyslipidemia (no [reference]/yes), diabetes (no [reference]/yes), and AST/ALT ratio.